The ORIGAMI Internal Condom™ (OIC) is a partner-initiated, internal condom designed to enhance sensation for both partners, improve ease of use, improve safety, provide direct tactile sensation, minimize slipping and breaking, and to accommodate a range of penis sizes. It replicates a fluid environment for the penis consistent with natural intercourse performance.
Unlike a conventional nitrile female condom, the transparent OIC is molded with anatomy-specific design. It's unique material tested 100% biocompatible and non-allergenic in independent pre-clinical lab testing.
The OFC is inserted vaginally before intercourse. It is intended to provide a female controlled strategy for contraception and prevention of HIV/AIDS and STD/STI.
To reach the market the condom must be reviewed by the WHO, the CE-Mark (EU), and the FDA (US) to meet regulatory safety requirements. The OIC has completed Phase 1 clinical trials in San Francisco, CA. In July 2013, clinical data reported 67% consumer preference for the OIC compared with the FC2 that reported only 16% preference among women and their men partners. The OIC is expected to reach the market in late 2016, pending regulatory pre-market reviews with the CE-Mark, WHO, and the FDA.